An editorial suggests that on the basis of these data, targeted oral therapy may have a role in the treatment of selected patients who have osteomyelitis and the health care infrastructure to support close monitoring, but it cautions that at this time, it is premature to recommend a widespread early switch to oral therapy for bone and joint infection. It calls for further studies to confirm these findings and further inform these strategies and advance stewardship to decrease antimicrobial resistance.